Claim Missing Document
Check
Articles

Found 12 Documents
Search
Journal : Jurnal Biomedika

The Sensitivity Test of Mycobacterium tuberculosis to Snail Seromucoid and Chitosan in vitro Yusup Subagio Sutanto; Magdalena Sutanto; Agnes Sri Harti; Nony Puspawati
Biomedika Vol 14 No 1 (2021): Jurnal Biomedika
Publisher : Fakultas Ilmu Kesehatan Universitas Setia Budi Surakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31001/biomedika.v14i1.1128

Abstract

Tuberculosis (TB) is an infection caused by M. tuberculosis (MTb) and is transmitted through droplets of phlegm in the air from patients or those suspected of having TB. In general, treatment for TB is done with anti-tuberculosis drugs (ATDs), specifically streptomycin, isoniazid, rifampicin, and ethambutol (SIRE) that takes a long time due to the level of resistance of MTb bacteria. The resistance of MTb triggers ATDs based on natural bioactive compounds. Chitosan as a result of chitin deacetylation can function as an antimicrobial agent because it is polycationic, which is biodegradable, biocompatible, and non-toxic. Snail (Achatina fulica) seromucoid contains antibacterial bioactive compounds, namely glycans, peptides, glycopeptides, achasin protein, and chondroitin sulfate. This study aims at testing the sensitivity of MTb isolates against snail seromucoid and chitosan in vitro. This research applied the experimental research method. MTb isolates were obtained from sputum samples of patients suspected of TB at the Surakarta Regional Public Hospital (RSUD Surakarta). The results of screening for MTb were positive, based on the microscopic examination of MTb using the Ziehl Nelson (ZN) method, the MPT 64 rapid test, and the quick molecular test using the Genexpert method. The research was completed through several stages, including the preparation of a suspension of germs with a concentration of 1 mg/ml or Mc. Farland 0.5-1.0; preparation of the stock solution and working solution (WS); drug sensitivity test (DST) against snail seromucoid; chitosan and ATDs (SIRE) on Lowenstein Jensen (LJ) media; and incubation at 37°C for 3-4 weeks. The results were interpreted on day 28 or day 42. The results have revealed that MTb isolates are 100% resistant to snail seromucoid and 2% chitosan. This study concludes that MTb isolates from suspected TB are resilient to 100% snail seromucoid and 2% chitosan.
The Potential and Effectiveness of Snail Seromucoid and Chitosan as Bioimmunostimulators Harti, Agnes Sri; Sutanto, Yusup Subagio; Puspawati, Nony
Biomedika Vol 15 No 2 (2022): Jurnal Biomedika
Publisher : Fakultas Ilmu Kesehatan Universitas Setia Budi Surakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31001/biomedika.v15i2.1448

Abstract

The host's cellular immune response plays an important role in the process of eliminating microorganisms that cause infection. Substances that can stimulate an increase in the immune response are called immunostimulators. Snail seromucoid contains bioactive compounds such as glycans, peptides, glycopeptides and chondroitin sulfate. Chitosan as an antimicrobial agent can be used in the biomedical field because chitosan has a number of hydroxyl groups (OH) and amine groups (NH2). The research objective was to determine the potency and effectiveness of snail seromucoid and chitosan as bioimmunostimulators. The research method is based on laboratory experimental results with the research stages, namely the analysis of the effectiveness of seromucoid and chitosan on lymphocyte proliferation. The results of the one way ANOVA analysis showed a p value of 0.000 so that there was a significant effect between the treatment groups, namely the effect of giving chitosan 65 ug/ml; snail mucus 65 ug/mL and a combination of chitosan (65 ug/mL) and snail mucus (65 ug/mL) ratio of 1:1, can increase lymphocyte proliferation optimally. This shows that snail mucus, chitosan and their combination in a 1:1 ratio are effective as BRM (Biological Response Modifier). It is hoped that the contribution of the results of this study can be further developed in the bioformulation of snail seromucoid preparations and chitosan as therapeutic agents for infectious diseases, including Acute Respiratory Distress Syndrome (ARDS), Tuberculosis and other diseases.